Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Hanmi And Merck in Discussion to Sell Hanmi's Hypertension Drug In Other Countries including Six Asia-Pacific Countries

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Hanmi Pharmaceutical and MSD are pushing to sell Hanmi's incrementally modified hypertensive amlodipine product Amosartan in other countries includng six Asia-Pacific countries under Merck's brand Cozzar XQ
Advertisement

Related Content

Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?
Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
Hanmi First Korean Firm To Follow U.S. FDA 505(b)(2) Pathway; AstraZeneca Files Suit For Nexium
South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products
Merck And Hanmi Partner In First Of A Kind Deal In South Korea
Merck And Hanmi Partner In First Of A Kind Deal In South Korea
Advertisement
UsernamePublicRestriction

Register

SC074964

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel